Heidi Maria Namløs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Heidi Maria Namløs has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Cleton-Jansen
Department of Pathology Leiden University Medical Center Leiden The Netherlands
1 shared publication - Antonio Llombart-Bosch
Pathology Department, University of Valencia, 46010 Valencia, Spain
1 shared publication - Esther Hauben
Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium
1 shared publication - Isidro Machado
Pathology Department, University of Valencia, 46010 Valencia, Spain
1 shared publication - Kjetil Boye
Department of Oncology, Oslo University Hospital, Oslo, Norway
1 shared publication - Leonardo A. Meza-Zepeda
Department of Tumour Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
1 shared publication
Latest Publications
- Open Access
- 1 April 2020
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 72, 100827
Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
- 1 April 2020
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 72, 100827
Open AccessCell-free DNA in blood as a noninvasive insight into the sarcoma genome
- Open Access
- 20 September 2011
- Published by Springer Nature in BMC Medical Genomics
- Vol. 4 (1) , 66
mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
Background: Conventional high-grade osteosarcoma is a primary malignant bone tumor, which is most prevalent in adolescence. Survival rates of osteosarcoma patients have not improved significantly in the last 25 years. Aiming to increase this survival rate, a variety of model systems are used to study osteosarcomagenesis and to test new therapeutic agents. Such model systems are typically generated from an osteosarcoma primary tumor, but undergo many changes due to culturing or interactions with a different host species, which may result in differences in gene expression between primary tumor cells, and tumor cells from the model system. We aimed to investigate whether gene expression profiles of osteosarcoma cell lines and xenografts are still comparable to those of the primary tumor.Methods: We performed genome-wide mRNA expression profiling on osteosarcoma biopsies (n = 76), cell lines (n = 13), and xenografts (n = 18). Osteosarcoma can be subdivided into several histological subtypes, of which osteoblastic, chondroblastic, and fibroblastic osteosarcoma are the most frequent ones. Using nearest shrunken centroids classification, we generated an expression signature that can predict the histological subtype of osteosarcoma biopsies.Results: The expression signature, which consisted of 24 probes encoding for 22 genes, predicted the histological subtype of osteosarcoma biopsies with a misclassification error of 15%. Histological subtypes of the two osteosarcoma model systems,i.e. osteosarcoma cell lines and xenografts, were predicted with similar misclassification error rates (15% and 11%, respectively).Conclusions: Based on the preservation of mRNA expression profiles that are characteristic for the histological subtype we propose that these model systems are representative for the primary tumor from which they are derived.
- 20 September 2011
- Published by Springer Nature in BMC Medical Genomics
- Vol. 4 (1) , 66
Open AccessmRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
Background: Conventional high-grade osteosarcoma is a primary malignant bone tumor, which is most prevalent in adolescence. Survival rates of osteosarcoma patients have not improved significantly in the last 25 years. Aiming to increase this survival rate, a variety of model systems are used to study osteosarcomagenesis and to test new therapeutic agents. Such model systems are typically generated from an osteosarcoma primary tumor, but undergo many changes due to culturing or interactions with a different host species, which may result in differences in gene expression between primary tumor cells, and tumor cells from the model system. We aimed to investigate whether gene expression profiles of osteosarcoma cell lines and xenografts are still comparable to those of the primary tumor.Methods: We performed genome-wide mRNA expression profiling on osteosarcoma biopsies (n = 76), cell lines (n = 13), and xenografts (n = 18). Osteosarcoma can be subdivided into several histological subtypes, of which osteoblastic, chondroblastic, and fibroblastic osteosarcoma are the most frequent ones. Using nearest shrunken centroids classification, we generated an expression signature that can predict the histological subtype of osteosarcoma biopsies.Results: The expression signature, which consisted of 24 probes encoding for 22 genes, predicted the histological subtype of osteosarcoma biopsies with a misclassification error of 15%. Histological subtypes of the two osteosarcoma model systems,i.e. osteosarcoma cell lines and xenografts, were predicted with similar misclassification error rates (15% and 11%, respectively).Conclusions: Based on the preservation of mRNA expression profiles that are characteristic for the histological subtype we propose that these model systems are representative for the primary tumor from which they are derived.